Stonebridge Capital Management’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Stonebridge Capital Management’s Portfolio ECYT Stock Details ECYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-21,650	Closed	-$515K	–	192
2014 Q1	$515K	Sell	21,650 -35,905	-62%	-$521K	0.21%	103
2013 Q4	$615K	Buy	57,555 +34,405	+149%	+$380K	0.25%	83
2013 Q3	$309K	Sell	23,150 -3,635	-14%	-$57.5K	0.14%	135
2013 Q2	$352K	Buy	+26,785	New	+$361K	0.16%	125

Other funds holding ECYT

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return

BIM

Bogle Investment Management Newton Lower Falls, Massachusetts $63M AUM 51.97% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Pacific Alternative Asset Management Company (PAAMCO) Irvine, California $913M AUM 18.29% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Stonebridge Capital Management's ECYT Position: Q2 2014 in Review

Stonebridge Capital Management sold out of Endocyte, Inc. Common Stock (ECYT) in Q2 2014, closing a stake of 21,650 shares — an estimated $515K sold.

Stonebridge Capital Management first reported a position in ECYT in Q2 2013 and held it in 4 quarters. The position peaked at $615K in Q4 2013. 101 funds tracked by Wall St. Rank hold ECYT as of Q2 2014.

Stonebridge Capital Management reported no remaining Endocyte, Inc. Common Stock position as of Q2 2014 after selling out during the quarter.
Stonebridge Capital Management sold 21,650 Endocyte, Inc. Common Stock shares in Q2 2014, an estimated $515K.
Stonebridge Capital Management first reported a position in Endocyte, Inc. Common Stock in Q2 2013 and held it in 4 quarters.
Stonebridge Capital Management's Endocyte, Inc. Common Stock position peaked at $615K in Q4 2013.
101 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q2 2014.

Based on Stonebridge Capital Management's 13F filing for Q2 2014, filed 16 Jul 2014.